China Lures Foreign Patients With Cutting-Edge, Cheap Medical Care 35
An anonymous reader quotes a report from Bloomberg: While traditional hotspots in the region such as Thailand, South Korea and Malaysia focus on services such as cosmetic surgery, IVF or physicals, China is trying to differentiate itself by providing some of the world's most advanced procedures. "There are two reasons why a patient travels for medical treatments: availability of advanced treatments and price," said Victor Cao, operations director of Joyful Medical, an agency in Shanghai that connects international patients to advanced cancer therapies in China. "Chinese people used to travel overseas for treatments that were not available at home, but now tables have turned."
As expanding visa-free policies eased travel in the past year or so, videos are proliferating on social media of foreigners recounting their positive experiences of treatment in China, usually for consumer procedures like acupuncture and tooth scaling. But one treatment that's more quietly gaining traction is CAR-T, among the most promising breakthroughs in oncology but unavailable in most countries, or extremely costly. The process sees doctors collect T cells from the patient's blood then modify them in a lab to produce a special receptor, CAR, that can bind to a specific protein on cancer cells. These engineered cells are then multiplied into large numbers and infused back into the patient. The CAR-T cells seek out cancer cells carrying the target antigen and kill them. In the US, one single infusion can cost between $300,000 to $475,000, according to the American Cancer Society. In China, the equivalent costs about $150,000 to $180,000, and it could get even cheaper -- its drug regulator recently accepted a marketing application for a therapy aimed to be priced below 300,000 yuan ($44,000).
China's medical tourism market remains in its infancy. Lecheng International Medical Tourism Pilot Zone in Hainan, which was designated as the country's only special medical zone in 2013, treated just a few thousand foreign medical tourists last year, compared to hundreds of thousands of domestic patients who visited. There, patients can access advanced drugs, devices, and therapies approved in other countries but not elsewhere in mainland China. But China is pushing to upgrade its economy and reshape its global image from just a manufacturing hub into a provider of high-value services, and demand for medical tourism is surging. Globally, the market is estimated at around $34 billion and expected to reach $126 billion by 2035, according to San Francisco-based Grand View Research. Meanwhile, China's sector is projected to grow from $1.3 billion in 2025 to $3.4 billion by 2035, according to New York-based firm Market Research Future. "The patients chose China for something they can't get at home," said Shi Haoying, the group's founder and chief executive officer. "I think the growing attention to medical tourism to China is the inevitable result of long-term accumulation and development in many areas, such as growing medical technologies, quality of service and cost-effectiveness."
Jeroen Groenewegen-Lau, an analyst at the Mercator Institute for China Studies, added: "Many new treatments, including in very advanced areas, are made in China but too advanced for the state of its healthcare system and the ability of its patients to pay for these things. It's in China's interest to integrate into the international system."
As expanding visa-free policies eased travel in the past year or so, videos are proliferating on social media of foreigners recounting their positive experiences of treatment in China, usually for consumer procedures like acupuncture and tooth scaling. But one treatment that's more quietly gaining traction is CAR-T, among the most promising breakthroughs in oncology but unavailable in most countries, or extremely costly. The process sees doctors collect T cells from the patient's blood then modify them in a lab to produce a special receptor, CAR, that can bind to a specific protein on cancer cells. These engineered cells are then multiplied into large numbers and infused back into the patient. The CAR-T cells seek out cancer cells carrying the target antigen and kill them. In the US, one single infusion can cost between $300,000 to $475,000, according to the American Cancer Society. In China, the equivalent costs about $150,000 to $180,000, and it could get even cheaper -- its drug regulator recently accepted a marketing application for a therapy aimed to be priced below 300,000 yuan ($44,000).
China's medical tourism market remains in its infancy. Lecheng International Medical Tourism Pilot Zone in Hainan, which was designated as the country's only special medical zone in 2013, treated just a few thousand foreign medical tourists last year, compared to hundreds of thousands of domestic patients who visited. There, patients can access advanced drugs, devices, and therapies approved in other countries but not elsewhere in mainland China. But China is pushing to upgrade its economy and reshape its global image from just a manufacturing hub into a provider of high-value services, and demand for medical tourism is surging. Globally, the market is estimated at around $34 billion and expected to reach $126 billion by 2035, according to San Francisco-based Grand View Research. Meanwhile, China's sector is projected to grow from $1.3 billion in 2025 to $3.4 billion by 2035, according to New York-based firm Market Research Future. "The patients chose China for something they can't get at home," said Shi Haoying, the group's founder and chief executive officer. "I think the growing attention to medical tourism to China is the inevitable result of long-term accumulation and development in many areas, such as growing medical technologies, quality of service and cost-effectiveness."
Jeroen Groenewegen-Lau, an analyst at the Mercator Institute for China Studies, added: "Many new treatments, including in very advanced areas, are made in China but too advanced for the state of its healthcare system and the ability of its patients to pay for these things. It's in China's interest to integrate into the international system."